Literature DB >> 12518719

Strategies to improve access to sterile syringes for injection drug users.

Josiah D Rich1, Francis A Wolf, Grace Macalino.   

Abstract

The high prevalence of infection with HIV and other blood-borne pathogens in injection drug users (IDUs) is directly related to the lack of syringe access. Needle exchange programs (NEPs), syringe prescription, and syringe deregulation are 3 approaches to increasing access to sterile syringes for IDUs. The benefits of NEPs have been repeatedly demonstrated, but the impact of NEPs has been limited by a lack of federal funding. Syringe prescription for IDUs is a promising new strategy supported by many organizations; legalizing syringe purchase and possession has led to a substantial improvement in syringe access in many states. Because each approach has unique advantages, providing IDUs with a variety of options for syringe access is likely to be most beneficial.

Entities:  

Mesh:

Year:  2002        PMID: 12518719

Source DB:  PubMed          Journal:  AIDS Read        ISSN: 1053-0894


  4 in total

1.  Non-prescription syringe sales in California: a qualitative examination of practices among 12 local health jurisdictions.

Authors:  Valerie J Rose; Glenn Backes; Alexis Martinez; Willi McFarland
Journal:  J Urban Health       Date:  2010-07       Impact factor: 3.671

2.  An external evaluation of a peer-run "unsanctioned" syringe exchange program.

Authors:  Evan Wood; Thomas Kerr; Patricia M Spittal; William Small; Mark W Tyndall; Michael V O'Shaughnessy; Martin T Schechter
Journal:  J Urban Health       Date:  2003-09       Impact factor: 3.671

3.  Access to sterile syringes through San Francisco pharmacies and the association with HIV risk behavior among injection drug users.

Authors:  Elise D Riley; Alex H Kral; Thomas J Stopka; Richard S Garfein; Paul Reuckhaus; Ricky N Bluthenthal
Journal:  J Urban Health       Date:  2010-07       Impact factor: 3.671

4.  A success story: HIV prevention for injection drug users in Rhode Island.

Authors:  Curt G Beckwith; Carla C Moreira; Hesham M Aboshady; Nickolas Zaller; Josiah D Rich; Timothy P Flanigan
Journal:  Subst Abuse Treat Prev Policy       Date:  2006-12-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.